Loading...

Recent search criteria

Media
- Media
- Press Releases
Investors
Partnering
Careers
- Careers
- Careers
- Working at Ipsen
- Culture

Loading...
United States
< Back
- Global EN FR
- Annual Report EN FR
United States

Brazil

Canada EN

Canada FR

Australia

China

Singapore

South Korea

Belgium

Ukraine

UK

Germany

France

Nordics

Greece

Italy

Netherlands

Spain

Poland

Russia

Slovakia

Czech Republic

Home
Company
- Company
- Company
- Leadership
- Our History
Science
- Science
- Areas of focus
- Products
- Clinical Trials
- R&D
- Grant Requests
- Investigator Sponsored Studies
Responsibility
- Responsibility
- Responsibility
- Environment
- Patients
- People
- Governance
- Charitable Contributions
Patients
- Patients
- Patients
- Early Access Public Policy
Stories

Home
Stories
Midsize with a Big Vision story

Epizyme welcome to Ipsen

Back

Post navigation

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

Epizyme welcome to Ipsen

- 12 August 2022 - 1 mins read

Epizyme welcome to Ipsen

Hear what CEO David Loew has to say about the official close of its acquisition of Epizyme.

Post navigation

Share this on social media

Related Stories

31 January 2024 4 mins read

Closing Gaps in Cancer Care – Together

IPN price

€114.40

€-0.20 (-0.17%)

Media
Investors
Partnering

Leadership
Responsibility
Patients
Stories

Contact us

Terms of Use
Cookies
Privacy
Compliance
Vigilance Alert: Identity Theft
U.S. Price Disclosures

Copyright © Ipsen Biopharmaceuticals, Inc. MP-US-000472. All rights reserved - 2024

ou are now leaving the Ipsen US website. To continue, please click on continue.